References
- World Health Organization. Cancer. 2022. https://www.who.int/news-room/fact-sheets/detail/cancer
- Wang L, Song Y, Wang H, et al. Advances of artificial intelligence in anti-cancer drug design: a review of the past decade. Pharmaceuticals (Basel, Switzerland). 2023;16(2):253. doi:10.3390/ph16020253
- Gupta R, Srivastava D, Sahu M, Tiwari S, Ambasta RK, Kumar P. Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Mol Divers. 2021;25(3):1315–1360. doi:10.1007/s11030-021-10217-3
- Okereke M, David KB, Adedeji OJ. Computational approaches to targeting protein–protein interactions in cancer: a pathway to drug discovery. Future Drug Discovery. 2023;(0):FDD80. doi:10.4155/fdd-2023-0003
- Liang G, Fan W, Luo H, Zhu X. The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomed Pharmacother. 2020;128:110255. doi:10.1016/j.biopha.2020.110255
- Pantuck AJ, Lee D, Kee T, et al. Modulating BET Bromodomain inhibitor ZEN-3694 and Enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE.AI, an artificial intelligence platform. Advanced Therapeutics. 2018;1(6):1800104. doi:10.1002/adtp.201800104
- Sampat B. A Survey of Empirical Evidence on Patents and Innovation. 2018. https://www.nber.org/system/files/working_papers/w25383/w25383.pdf
- Okeniyi SO, Okereke M. Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market. Pharmaceutical patent analyst. 2022;11(5):131–133. doi:10.4155/ppa-2022-0044
- Patra MC, Choi S. Recent progress in the development of Toll-like receptor (TLR) antagonists. Exp Opin on Therap Paten. 2016;26(6):719–730. doi:10.1080/13543776.2016.1185415
- Otsuka Y. Prokaryotic toxin-antitoxin systems: novel regulations of the toxins. Curr Genet. 2016;62(2):379–382. doi:10.1007/s00294-015-0557-z
- Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct activation of bax protein for cancer therapy. Med Res Rev. 2016;36(2):313–341. doi:10.1002/med.21379
- Ortiz R, Prados J, Melguizo C, et al. Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells. BiomedPharmacotherapy. 2012;66(7):563–567. doi:10.1016/j.biopha.2012.05.004
- Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G. Predictive biomarkers for cancer therapy with PARP inhibitors. Oncogene. 2014;33(30):3894–3907. doi:10.1038/onc.2013.352
- Yang WZ, Zhang T. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2022;43(5):627–633. doi:10.3760/cma.j.cn112338-20220210-00106
- Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharmaceut., 2018;15(10):4311–4313. doi:10.1021/acs.molpharmaceut.8b00930
- Blanco-González A, Cabezón A, Seco-González A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals (Basel, Switzerland). 2023;16(6):891. doi:10.3390/ph16060891
- Rashid M. Design, synthesis and ADMET prediction of bis-benzimidazole as anticancer agent. Bioorg Chem. 2020;96:103576. doi:10.1016/j.bioorg.2020.103576
- Fahimian G, Zahiri J, Arab SS, Sajedi RH. RepCOOL: computational drug repositioning via integrating heterogeneous biological networks. J Translat Medicine. 2020;18(1):375. doi:10.1186/s12967-020-02541-3
- Wang Y, Dou X, Jiang L, et al. Discovery of novel glycogen synthase kinase-3α inhibitors: structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia. European J Medic Chem. 2019;171:221–234. doi:10.1016/j.ejmech.2019.03.039
- Trappey AJ, Trappey CV, Wu JL, Wang JW. Intelligent compilation of patent summaries using machine learning and natural language processing techniques. Advan Engin Inform. 020;43:101027. doi:10.1016/j.aei.2019.101027